Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival
- 137 Downloads
Methylation in IKZF1 and BCAT1 are common events in colorectal cancer (CRC). They are often detected in blood as circulating tumor DNA (ctDNA) at diagnosis and disappear after surgery in most CRC patients. A prospective study was conducted to determine the relationship between detection of these markers following surgery and risk for residual disease and for recurrence.
ctDNA status with methylated BCAT1 and IKZF1 was determined within 12 months of surgical resection of CRC, and was related to presence of or risk for residual disease (margins involved, metastases present or nature of node involvement), and to recurrence-free survival.
Blood was collected from 172 CRC patients after surgery and 28 (16%) were ctDNA positive. Recurrence was diagnosed in 23 of the 138 with clinical follow-up after surgery (median follow-up 23.3 months, IQR 14.3–29.5). Multivariate modeling indicated that features suggestive of residual disease were an independent predictor of post-surgery ctDNA status: cases with any of three features (close resection margins, apical node involved, or distant metastases) were 5.3 times (95% CI 1.5–18.4, p = 0.008) more likely to be ctDNA positive. Multivariate analysis showed that post-surgery ctDNA positivity was independently associated with an increased risk of recurrence (HR 3.8, 1.5–9.5, p = 0.004).
CRC cases positive for methylated ctDNA after surgery are at increased risk of residual disease and subsequently recurrence. This could have implications for guiding recommendations for adjuvant therapy and surveillance strategies. Randomized studies are now indicated to determine if monitoring cases with these biomarkers leads to survival benefit.
KeywordsColorectal cancer (CRC) Circulating tumor DNA (ctDNA) Survival Residual disease Methylated DNA
GPY and CK are recipients of a grant funded by the financial support of Cancer Council SA’s Beat Cancer Project on behalf of its donors and the State Government of South Australia through the Department of Health together with the support of the Flinders Medical Centre Foundation, its donors and partners.
This study was funded in part by the National Health and Medical Research Council (APP1006242, APP1017083) and Clinical Genomics Pty Ltd.
Compliance with ethical standards
Conflict of interest
GPY is a paid consultant of Clinical Genomics. SKP and DHM are paid employees of Clinical Genomics. All other authors have no conflicts of interest to declare.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- Edge SB, Byrd DR, Compton CC et al (2010) AJCC cancer staging manual, 7 edn. Springer, New YorkGoogle Scholar
- Niedzwiecki D, Bertagnolli MM, Warren RS et al (2011) Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. J Clin Oncol 29:3146–3152. https://doi.org/10.1200/JCO.2010.32.5357 CrossRefPubMedPubMedCentralGoogle Scholar
- Noah TK, Shroyer NF (2013) Notch in the intestine: regulation of homeostasis and pathogenesis. Annu Rev Physiol 75:263–288. https://doi.org/10.1146/annurev-physiol-030212-183741 CrossRefPubMedGoogle Scholar